Skip to main content

Stroke Management through RGTA®: SMR


Stroke is the 2nd cause of death and major handicaps in industrialized countries. At present, the only available treatment for ischemic stroke are thrombolysis and thrombectomy. However, very few patients are eligible, and it is therefore absolutely urgent to find an alternative.
RGTA® are synthetic polysaccharides, mimicking endogenous macro-molecules called heparan sulphates, that make up the biological networks in which our cells live and reproduce: the extracellular matrix.
We have recently investigated the neuroprotective potential of a novel specific RGTA® (OTR4132) at the preclinical level using a rodent model of transient focal cerebral ischemia The i.v. administration of OTR4132-MD elicited a reduction of 39,6% of the volume of infarction at 48 hours following the insult. Interestingly, this RGTA®-induced reduction of brain damage persisted up to the chronic stage and RGTA®-treated animals showed a significant improvement of functional recovery (motor and sensorial) when compared to control animals.
Translational stroke studies in rodent models have thus already demonstrated the beneficial effects of RGTA® in acute phase and, following additional preclinical studies in an independent laboratory, the project will be ready for next stages of its route to market introduction, including clinical validation and product registration. The objective of the SMR project is to translate experimental findings into medical innovation, leading to a quick benefit for stroke patients. Positive outcomes of the project will lead rapidly to the EU registration of OTR4132-MD injectable solution as a medical device or a drug and to its market introduction in Europe for the stroke indication.

Call for proposal

See other projects for this call


Rue Francaise 4
75001 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 382 940